6-溴吡啶-2-甲酰胺 | 25194-52-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-溴吡啶-2-甲酰胺
• 中文别名: 6-溴吡啶甲酰胺
• 英文名称: 6-bromopyridine-2-carboxamide
• 英文别名: 6-bromopicolinamide；6-bromo-pyridine-2-carboxylic acid amide
• CAS: 25194-52-9
• 化学式: C₆H₅BrN₂O
• 分子量: 201.023
• InChiKey: HWRUOHMDYQEWOD-UHFFFAOYSA-N

物化性质

• 熔点：
  133-138°C
• 沸点：
  338.1±27.0 °C(Predicted)
• 密度：
  1.710±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S28,S45
• 危险类别码：
  R22,R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险标志：
  GHS07
• 危险性描述：
  H302,H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromopicolinamide
Synonyms: 6-Bromo-2-pyridinecarboxamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromopicolinamide
CAS number: 25194-52-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H5BrN2O
Molecular weight: 201.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴吡啶-2-甲酰胺 在 氯化亚砜 作用下， 以 乙腈 为溶剂， 以92 %的产率得到2-溴-6-氰基吡啶
  参考文献：
  名称：

  一种2-溴-6-氰基吡啶的合成方法

  摘要：

  本发明公开了一种2‑溴‑6‑氰基吡啶的合成方法，以2‑溴‑6‑羧酸吡啶为起始原料，依次经过酰化反应、氨解反应、脱水反应得到所述2‑溴‑6‑氰基吡啶。本发明2‑溴‑6‑氰基吡啶的合成方法，反应条件温和、收率高、成本低、原料易得、可工业化生产，且氯化亚砜反应液可以反复套用，提高原料的利用率，减少资源浪费，减少污染，最大程度的降低整体工艺的生产成本，具有极高的应用价值。

  公开号：

  CN115417814A
• 作为产物：
  描述：

  6-溴-2-吡啶甲酸甲酯 在 氨 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以955 mg的产率得到6-溴吡啶-2-甲酰胺
  参考文献：
  名称：

  苯氧苯基吡啶是新型的状态依赖性，高效钠通道抑制剂。

  摘要：

  为了寻找更有效的治疗神经性疼痛状态的药物，基于4-（4-氟苯氧基）苯甲醛半卡巴zone设计了一系列苯氧苯基吡啶。通过改变吡啶环上的取代基，鉴定了几种有效的状态依赖性钠通道抑制剂。从这些化合物中，在神经性疼痛的Chung模型中，有23种剂量依赖性逆转了触觉异常性疼痛。口服10 mg / kg的逆转水平约为。50％，相当于以100 mg / kg口服卡马西平的效果。

  DOI：

  10.1021/jm040048d

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS<br/>[FR] DERIVES DE BENZOFURANE UTILISES POUR TRAITER DES TROUBLES HYPERPROLIFERANTS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005014566A1

  公开（公告）日：2005-02-17

  The invention relates to novel heterocycles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.

  这项发明涉及到式(I)的新异环化合物，以及用于制备这些化合物的方法，以及它们用于制备治疗或预防疾病的药物，特别是治疗过度增殖性疾病的药物。
• [EN] PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE TRIAZINE, ET LEUR UTILISATION COMME INHIBITEURS D'AXL
  申请人：PFIZER

  公开号：WO2016097918A1

  公开（公告）日：2016-06-23

  Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  公式(I)的化合物： (I) 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。
• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160159773A1

  公开（公告）日：2016-06-09

  The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等）等的药剂，其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的，或其盐。
• [EN] SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS AMINÉS À SUBSTITUTION ARYLE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006012374A1

  公开（公告）日：2006-02-02

  The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

  本发明提供了一类化合物，包括其药用可接受的衍生物，用于治疗血管生成和相关疾病，如癌症。其中R为从7-异喹啉基、2-甲基-3-氧代-2,3-二氢吲哚-6-基、[1,6]-萘啶-3-基、[1,7]-萘啶-2-基、1-氧代-2,3-二氢苯并呋喃-4-基、3-氧代-2,3-二氢苯并呋喃-5-基、二氢苯并二氧杂环基、6-喹唑啉基、2-氨基-6-喹唑啉基、4-甲氨基-6-喹唑啉基、2,4-二氨基-6-喹唑啉基、3-氧代-3,4-二氢-1,4-苯并噁嗪-6-基、2,2-二氟-1,3-苯并二氧杂环-5-基和2,2,3,3-四氟-2,3-二氢-1,4-苯并二氧杂环-6-基中选择的9-或10-成员杂环基，其中每个基可选择地被一个或多个来自卤素、卤代烷基、C1-6烷基、C2-8烯基、C2-8炔基、N-二甲氨基-C1-6-烷基、N-二甲氨基-C1-6-烷氧基、氨基、烷基-羰基氨基、吗啉磺酰基、氨基磺酰基、噁唑基、吡咯基、吗啉基、羧基、氰基和乙酰基的取代基取代；其中式I中的R1从未取代或取代的苯基、5-6成员杂芳基、9-10成员双环杂环基和11-14成员三环杂环基中选择，式II中的R1从特定的双环杂环基中选择。